Philogen Provides Corporate Update
Philogen Provides Corporate Update Nidlegy™ and Fibromun on track with planned timelines in pivotal clinical trials Use of Nidlegy™ in non-melanoma skin cancer expanded in Phase II clinical trials Early evidence of potent activity of Fibromun in combination with Standard of Care in last line patients with Glioblastoma and Soft Tissue Sarcoma Clinical experience with […]
Continue Reading